ストックスクリーナーアプリを入手
84.22
0.01%
0.01
アフターアワーズ：
84.36
0.14
+0.17%
前日終値:
$84.21
開ける：
$84.26
24時間の取引高:
8.26M
Relative Volume:
0.59
時価総額：
$210.36B
収益：
$63.43B
当期純損益:
$16.42B
株価収益率:
12.98
EPS:
6.49
ネットキャッシュフロー:
$14.72B
1週間 パフォーマンス:
+5.24%
1か月 パフォーマンス:
+5.33%
6か月 パフォーマンス:
+1.12%
1年 パフォーマンス:
-25.91%
1日の値動き範囲:
$84.08
$85.14
1週間の範囲:
$79.67
$85.14
52週間の値動き範囲:
$73.31
$120.30
Merck Co Inc Stock (MRK) Company Profile
MRK を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MRK
Merck Co Inc
|
84.22 | 210.34B | 63.43B | 16.42B | 14.72B | 6.49 |
|
LLY
Lilly Eli Co
|
698.05 | 628.62B | 53.26B | 13.80B | -50.20M | 15.30 |
|
JNJ
Johnson Johnson
|
176.25 | 425.41B | 90.62B | 22.66B | 18.18B | 9.35 |
|
ABBV
Abbvie Inc
|
206.57 | 365.13B | 58.33B | 3.73B | 18.24B | 2.10 |
|
NVS
Novartis Ag Adr
|
124.01 | 240.45B | 53.40B | 13.68B | 16.89B | 6.9231 |
Merck Co Inc Stock (MRK) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-05-14 | ダウングレード | Citigroup | Buy → Neutral |
| 2025-04-22 | 開始されました | Cantor Fitzgerald | Neutral |
| 2025-02-18 | ダウングレード | Deutsche Bank | Buy → Hold |
| 2025-02-10 | ダウングレード | TD Cowen | Buy → Hold |
| 2025-01-08 | ダウングレード | Truist | Buy → Hold |
| 2024-12-20 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-10 | 再開されました | BofA Securities | Buy |
| 2024-12-04 | アップグレード | HSBC Securities | Hold → Buy |
| 2024-11-15 | 開始されました | Wolfe Research | Peer Perform |
| 2024-11-11 | ダウングレード | Daiwa Securities | Buy → Neutral |
| 2024-10-17 | 開始されました | Bernstein | Mkt Perform |
| 2024-03-11 | ダウングレード | Societe Generale | Hold → Sell |
| 2024-01-04 | アップグレード | TD Cowen | Market Perform → Outperform |
| 2023-11-09 | 開始されました | Deutsche Bank | Buy |
| 2023-10-27 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2023-10-20 | アップグレード | UBS | Neutral → Buy |
| 2023-07-14 | 開始されました | HSBC Securities | Hold |
| 2023-04-13 | アップグレード | Citigroup | Neutral → Buy |
| 2023-03-28 | ダウングレード | Societe Generale | Buy → Hold |
| 2023-03-13 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2023-03-06 | 開始されました | Jefferies | Buy |
| 2023-02-22 | アップグレード | Wolfe Research | Peer Perform → Outperform |
| 2023-01-04 | アップグレード | BofA Securities | Neutral → Buy |
| 2022-11-18 | 開始されました | Credit Suisse | Outperform |
| 2022-10-10 | アップグレード | Guggenheim | Neutral → Buy |
| 2022-09-14 | アップグレード | Berenberg | Hold → Buy |
| 2022-07-06 | アップグレード | Daiwa Securities | Neutral → Buy |
| 2022-06-06 | 再開されました | SVB Leerink | Outperform |
| 2022-04-06 | 再開されました | Morgan Stanley | Equal-Weight |
| 2021-12-17 | 開始されました | Goldman | Buy |
| 2021-12-16 | 開始されました | Daiwa Securities | Neutral |
| 2021-12-13 | ダウングレード | UBS | Buy → Neutral |
| 2021-12-09 | 開始されました | Wells Fargo | Overweight |
| 2021-12-07 | ダウングレード | Guggenheim | Buy → Neutral |
| 2021-11-29 | ダウングレード | Citigroup | Buy → Neutral |
| 2021-11-19 | 開始されました | BMO Capital Markets | Market Perform |
| 2021-11-01 | アップグレード | Argus | Hold → Buy |
| 2021-09-07 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-07-27 | 再開されました | Truist | Buy |
| 2021-05-20 | ダウングレード | Argus | Buy → Hold |
| 2021-04-07 | 再開されました | RBC Capital Mkts | Sector Perform |
| 2020-11-10 | 再開されました | Bernstein | Outperform |
| 2020-09-29 | 開始されました | Berenberg | Hold |
| 2020-08-03 | アップグレード | Goldman | Neutral → Buy |
| 2020-06-12 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
| 2020-02-27 | 開始されました | Barclays | Overweight |
| 2020-01-07 | 開始されました | RBC Capital Mkts | Sector Perform |
| 2019-10-17 | 再開されました | BofA/Merrill | Neutral |
| 2019-08-16 | 開始されました | SVB Leerink | Outperform |
| 2019-07-03 | 開始されました | Mizuho | Buy |
| 2019-05-28 | 開始されました | Goldman | Neutral |
| 2019-05-13 | アップグレード | Atlantic Equities | Neutral → Overweight |
| 2018-10-16 | 繰り返されました | Citigroup | Buy |
| 2018-10-09 | 再開されました | Guggenheim | Buy |
| 2018-04-23 | アップグレード | Goldman | Neutral → Buy |
| 2018-04-17 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2018-04-05 | アップグレード | Barclays | Equal Weight → Overweight |
| 2018-03-12 | アップグレード | Leerink Partners | Mkt Perform → Outperform |
| 2018-02-14 | 繰り返されました | Leerink Partners | Mkt Perform |
| 2018-02-07 | 繰り返されました | Morgan Stanley | Equal-Weight |
| 2018-01-16 | アップグレード | SunTrust | Hold → Buy |
すべてを表示
Merck Co Inc (MRK) 最新ニュース
Skyhawk’s small-molecule RNA efforts draw Merck KGaA in $2B deal - BioWorld MedTech
Skyhawk Flies High With Another Big Pharma, Getting Up To $2bn In Merck KGaA Deal - insights.citeline.com
PD-(L)1 Inhibitors Market Set to Surge During the Forecast Period (2025–2034) as Immuno-Oncology Therapies Gain Momentum | DelveInsight - GlobeNewswire Inc.
Merck KGaA Signs $2 Billion Neurology Drug Pact With Skyhawk - Bloomberg.com
Merck: Shares Bucking The Gardasil Problem, Hiking My Price Target - Seeking Alpha
Q3 EPS Estimates for Merck & Co., Inc. Cut by Zacks Research - Defense World
Janux Therapeutics Receives $10M Milestone Payment from Merck for Advancing Cancer Therapy Collaboration - MSN
Merck & Co., Inc. (MRK) Announces Update on Phase 3 KEYNOTE-905 Trial - MSN
Merck Stock: Buy The Weakness (NYSE:MRK) - Seeking Alpha
Austria Accepts Merck Commitments After ‘Predatory Pricing’ Undermined Generics - insights.citeline.com
Merck & Co., Inc. (MRK) Impresses Jim Cramer With Its Toughness - MSN
The Zacks Analyst Blog Highlights Merck, Palo Alto Networks, Freeport-McMoRan and Espey - Yahoo Finance
Top Analyst Reports for Merck, Palo Alto & Freeport - Yahoo Finance
10 Stocks Jim Cramer Discussed As He Questioned Official Data - Insider Monkey
Livestock Monitoring Company Evaluation Report 2025 | Merck & Co., GEA Group, and DeLaval Drive Global Innovations Across Biopharma, Process Technology, and Dairy Farming Automation - Yahoo Finance
Stock Watch: Sanofi And Merck Temper Big Pharma Q2 Earnings Cheer - insights.citeline.com
Goldman Sachs Slashes PT on Merck & Co. (MRK) to $94 From $99, Keeps a Buy Rating - MSN
What's Going On With Merck Stock Tuesday?Merck & Co (NYSE:MRK), Pfizer (NYSE:PFE) - Benzinga
IO Biotech's cancer vaccine shows improvement, but narrowly misses study goal - Reuters
Merck to Begin Phase 3 Trials for Investigational Monthly HIV Prevention Pill - MSN
Merck KGaA Plans $4 Billion Bond Sale to Fund SpringWorks Therapeutics Acquisition - Bloomberg.com
Merck & Co Stock Ends Higher After Volatile Session - thekhabrilal
Analysts Set Merck & Co., Inc. (NYSE:MRK) Price Target at $107.44 - Defense World
Critical Review: Merck & Co., Inc. (NYSE:MRK) and Johnson & Johnson (NYSE:JNJ) - Defense World
The departure of senior executives from Merck & Co Inc and Novartis triggered a "chain reaction". Heng Rui and Wise had intensive personnel changes in local pharmaceutical companies. Inventory of personnel changes in October. - 富途牛牛
Merck & Co. (MRK) Divests Surface Solutions for €665 million - MSN
Goldman Sachs Reduced the PT on Merck & Co., Inc. (MRK), Kept a Buy Rating - MSN
Verona’s COPD Launch Success Sealed Merck Buyout Interest - insights.citeline.com
Merck & Co Inc Options Trading: September 26th Expiration - AInvest
Investors Heavily Search Merck & Co., Inc. (MRK): Here is What You Need to Know - Yahoo Finance
United States Pharmaceutical Market Forecast and Company Analysis Report 2025-2033 Featuring F. Hoffmann-La Roche, Novartis, Abbvie, Johnson & Johnson, Merck, Pfizer, BMS, Sanofi, GSK, Takeda - Yahoo Finance
Merck & Co. (MRK) Slid on Weaker Market Sentiment and Concerns About Drug Pipeline - MSN
UBS Bullish on Merck (MRK) Following Verona Pharma Purchase - MSN
Palmetto Grain Brokerage - Palmetto Grain Brokerage
11 Cheap Pharmaceutical Stocks to Buy Now - Insider Monkey
Merck & Co., Inc. (MRK) Needs To Move On From Talking About Its Animal Division, Says Jim Cramer - MSN
Merck to Cut 6,000 Jobs as It Aims for $3 Billion in Cost Savings by 2027 - PharmExec
Oppenheimer Considers Merck & Co. (MRK) Agreement as Strong Endorsement for Veeva’s Vault CRM - MSN
Merck Co Inc (MRK) 財務データ
収益
当期純利益
現金流量
EPS
2.56%
0.16%
大文字化:
|
ボリューム (24 時間):